8-K: NKGen Secures $25.8M High-Interest Loan, Restructures Debt

NKGen Biotech and its subsidiary secured a $25.8 million secured promissory note from AlpineBrook Capital, consolidating prior advances and adding new capital, with significant collateral and restrictive covenants.

Summary

• NKGen Biotech, Inc. and NKGen Operating Biotech, Inc. (Borrowers) entered into a secured promissory note (the Note) with AlpineBrook Capital GP I Limited (Lender) on January 5, 2026.
• The Note has an original principal amount of $25,840,106, bearing interest at 12% per annum.
• The principal amount comprises $25,540,106 for undocumented cash advances made by the Lender since late 2024 (primarily for the acquisition of NKGen Biotech Korea Co., Ltd.) plus accrued interest, fees, and expenses.
• An additional $300,000 in new capital was advanced by the Lender contemporaneously with the Note's execution.
• The Note matures initially two months after issuance, subject to extension at the Lender's sole discretion.
• Prepayment is prohibited before the applicable maturity date without the Lender's prior written consent.
• A Most Favored Nation (MFN) provision applies to future debt or equity financings, granting the Lender the benefit of any more favorable terms.
• Upon a Change of Control, the Note requires repayment of outstanding principal, accrued interest, and a 20% cash premium on the outstanding principal amount.
• In the event of default, all outstanding obligations will bear default interest at a rate of 24% per annum.
• The Borrowers granted the Lender security interests in substantially all U.S. personal property, U.S. real property (via Deed of Trust and Assignment of Leases and Rents), and the Company's shares of NKGen Korea (Pledged Shares and Korean Account Collateral).
• All security interests are subordinate to existing liens of East West Bank and BDW Investments LLC and require their consents for perfection.
• The Company is required to use commercially reasonable best efforts to cause NKGen Korea to provide an unconditional guarantee of the Borrowers' obligations and a first-priority security interest over substantially all of NKGen Korea's assets, subject to board approval and waivers.
• The Lender also holds a Right of First Refusal (ROFR) over any proposed transfer of NKGen Korea shares by the Company.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the high cost of capital (12% interest, 24% default interest, 20% change of control premium), extensive collateral requirements, and highly restrictive covenants. While the financing provides liquidity and debt consolidation, the unfavorable terms suggest significant financial strain and limited options for the company.

Positives

• The company successfully secured financing, consolidating prior undocumented advances and receiving an additional $300,000 in new capital, which is necessary to support ongoing business operations.
• The financing provides a structured repayment term for existing debt, which was previously undocumented.

Negatives

• The Note carries a high interest rate of 12% per annum, indicating a high cost of capital for the Borrowers.
• A significant 20% cash premium is required on the outstanding principal amount upon a Change of Control, which could deter potential acquirers or make such transactions more expensive.
• The default interest rate is exceptionally high at 24% per annum, posing substantial financial risk if an Event of Default occurs.
• The Note includes extensive restrictive covenants limiting additional indebtedness, granting of liens, equity issuances, and changes to the capital structure, severely restricting the Borrowers' financial and strategic flexibility.
• The Most Favored Nation (MFN) provision could make future financing more challenging or expensive, as any more favorable terms offered to new lenders would also apply to AlpineBrook Capital.
• The requirement for NKGen Korea to provide an unconditional guarantee and a first-priority security interest over its assets, while subject to board approval and waivers, adds complexity and potential hurdles.

Risks

• Inability to obtain necessary consents from East West Bank and BDW Investments LLC for the perfection of security interests, potentially leaving the Lender's collateral unperfected.
• Failure to obtain NKGen Korea board approval or necessary waivers for the unconditional guarantee and first-priority security interest, which could constitute an Event of Default.
• The high interest rate and restrictive covenants increase the risk of financial distress and potential default.
• The MFN provision could negatively impact the terms of any future debt or equity financings, making them less attractive or more costly.
• A Change of Control event would trigger a substantial 20% premium payment, potentially hindering strategic alternatives.
• The extensive collateral package, including U.S. personal property, U.S. real property, and NKGen Korea shares, significantly limits unencumbered assets available for future financing or operational needs.
• The lock-up period on NKGen Korea shares delays the full perfection of the Kun-Pledge until after July 21, 2026.

Future Outlook

The company's immediate future outlook involves obtaining necessary third-party consents from East West Bank and BDW Investments LLC for the perfection of security interests, as well as securing board approval and waivers for NKGen Korea to provide an unconditional guarantee and a first-priority security interest over its assets. The maturity date of the loan is subject to the Lender's discretion, providing some uncertainty regarding the repayment timeline.

Management Comments

• No specific management quotes were provided in the filing beyond the signing of the document by Paul Y. Song, Chief Executive Officer.

Industry Context

This financing arrangement reflects the challenging capital-raising environment often faced by early-stage biotechnology companies, particularly those involved in complex acquisitions or with significant prior undocumented debt. The high interest rate, extensive collateral requirements, and restrictive covenants suggest that NKGen Biotech may have limited alternative financing options, indicating a higher perceived risk by lenders compared to more established industry players. Such terms are not uncommon for companies seeking to consolidate distressed or complex debt structures in the biotech sector, where R&D costs are high and commercialization timelines are long.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results to assess the terms of this financing against global industry benchmarks. Therefore, a direct comparison is not feasible based solely on the information provided.

Corporate Governance

Stakeholder Impact

• **Shareholders:** The high cost of debt, restrictive covenants, and potential for a 20% premium on a Change of Control could negatively impact shareholder value and limit future strategic options. The MFN clause could also hinder future equity raises.
• **Employees:** Securing this financing may provide short-term stability by addressing existing debt and providing some new capital, potentially safeguarding jobs. However, the company's long-term financial health under these terms remains a concern.
• **Creditors (East West Bank, BDW Investments LLC):** The new security interests are subordinate to their existing liens, but the requirement for their consents for perfection introduces a dependency.
• **NKGen Biotech Korea Co., Ltd.:** The requirement for NKGen Korea to provide an unconditional guarantee and a first-priority security interest over its assets could impact its own financial flexibility and future operations, subject to its board's approval.

Next Steps

• Obtain consents and approvals from East West Bank and BDW Investments LLC for the perfection of security interests.
• Execute and deliver the Deed of Trust and Assignment of Leases and Rents for U.S. real property collateral.
• Use commercially reasonable best efforts to cause NKGen Korea to provide an unconditional guarantee and a first-priority security interest over its assets, subject to board approval and waivers.
• Take actions to perfect the security interests in NKGen Korea shares and related accounts, particularly after the expiry of the lock-up period on July 21, 2026.

Key Dates

Recommendation

The terms of this secured promissory note are highly unfavorable, characterized by a substantial 12% interest rate, a punitive 24% default interest rate, and a significant 20% premium on a Change of Control. The extensive collateral package, covering nearly all company assets and requiring a guarantee from a key subsidiary (NKGen Korea), coupled with highly restrictive covenants and a Most Favored Nation clause, indicates a company in a distressed financial position with limited access to more favorable capital. While the financing provides immediate liquidity and debt consolidation, the long-term implications of such high-cost and restrictive debt are likely to severely constrain growth, operational flexibility, and shareholder value. A seasoned investor would view these terms as a strong signal of underlying financial weakness and significant risk, warranting a 'sell' recommendation.

Keywords

Biotech, Secured Promissory Note, Debt Financing, Corporate Governance, NKGen Korea, Collateral, Restrictive Covenants, High Interest Debt, Capital Raise, SEC Filing